MethylGene Inc. (TSX: MYG) a biopharmaceutical company focused on epigenetic regulation, today announced operational and financial results for the second quarter ended June 30, 2006.
MethylGene Inc. (TSX: MYG) a biopharmaceutical company focused on epigenetic regulation, today announced operational and financial results for the second quarter ended June 30, 2006.